The objective of this review is to perform a systematic review of the beneficial and harmful effects of vedolizumab subcutaneous injection for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response to, loss of response to, or were intolerant to either conventional therapy or infliximab, a tumour necrosis factor alpha antagonist.